Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: Evidence review and updated expert recommendations

European Urology

Volumn 66, Issue 5, 2014, Pages 863-871

  Witjes, J Alfred ^a   Babjuk, Marek ^b   Gontero, Paolo ^c   Jacqmin, Didier ^d   Karl, Alexander ^e   Kruck, Stephan ^f   Mariappan, Paramananthan ^g   Palou Redorta, Juan ^h   Stenzl, Arnulf ^f   Van Velthoven, Roland ⁱ   Zaak, Dirk ^j  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g WESTERN GENERAL HOSPITAL   (United Kingdom)

^h FUNDACIÓ PUIGVERT   (Spain)

ⁱ JULES BORDET INSTITUTE   (Belgium)

^j Traunstein Hospital   (Germany)

more..

Author keywords

Bladder cancer; Cost effectiveness; Fluorescence cystoscopy; Hexaminolevulinate; Quality adjusted life years; Recurrence

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; PROTOPORPHYRIN; 5-AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID;

BLADDER BIOPSY; BLADDER SURGERY; BLUE LIGHT CYSTOSCOPY; CANCER RECURRENCE; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; CYSTOSCOPY; FLUORESCENCE IMAGING; FOLLOW UP; HEALTH CARE SYSTEM; HEMATURIA; HOSPITALIZATION COST; HUMAN; META ANALYSIS; MYCOBACTERIUM BOVIS BCG; NON MUSCLE INVASIVE BLADDER CANCER; PERSONAL EXPERIENCE; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; SURGERY; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION OF BLADDER TUMOR; URINE CYTOLOGY; WHITE LIGHT CYSTOSCOPY; ANALOGS AND DERIVATIVES; COST BENEFIT ANALYSIS; CYSTECTOMY; DIAGNOSTIC USE; DISEASE COURSE; DISEASE FREE SURVIVAL; ECONOMICS; HEALTH CARE COST; MINIMAL RESIDUAL DISEASE; PATHOLOGY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROCEDURES; STANDARDS; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS;

AMINOLEVULINIC ACID; COST-BENEFIT ANALYSIS; CYSTECTOMY; CYSTOSCOPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84907586936     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.06.037     Document Type: Review

References (49)

1. International Agency for Research on Cancer. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr. Accessed February 2014.
2. R.J. Sylvester, A.P. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 475
3. M. Babjuk, M. Burger, and R. Zigeuner EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013 Eur Urol 64 2013 639 653
4. K.D. Sievert, B. Amend, and U. Nagele Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27 2009 295 300
5. H.W. Herr, and S.M. Donat Quality control in transurethral resection of bladder tumours BJU Int 102 2008 1242 1246
6. E.R. Ray, and T.S. O'Brien Approaches to reducing recurrence in superficial bladder cancer Eur Urol Rev 2005 1 6
7. I. Kausch, M. Sommerauer, and F. Montorsi Fluoreszenzdiagnostik bei Patienten mit nicht muskelinvasivem Harnblasenkarzinom: Ergebnisse einer Metaanalyse Aktuelle Urol 41 2010 171 177
8. I. Kausch, M. Sommerauer, and F. Montorsi Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies Eur Urol 57 2010 595 606
9. B.L. Isfoss The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard BJU Int 108 2011 1703 1707
10. S.P. Lerner, H. Liu, M.F. Wu, Y.K. Thomas, and J.A. Witjes Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder Urol Oncol 30 2012 285 289
11. P. Shen, J. Yang, and W. Wei Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis BJU Int 110 2012 E209 E215
12. H. Yuan, J. Qiu, and L. Liu Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials PLoS ONE 8 2013 e74142
13. M. Burger, H.B. Grossman, and M. Droller Photodynamic diagnosis of non-muscle invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis Eur Urol Suppl 12 2013 e577
14. M. Burger, H.B. Grossman, and M. Droller Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data Eur Urol 64 2013 846 854
15. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
16. M. Rink, M. Babjuk, and J.W.F. Catto Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature Eur Urol 64 2013 624 638
17. Scottish Intercollegiate Guidelines Network Management of transitional cell carcinoma of the bladder: a national clinical guideline. SIGN 85. Edinburgh, UK: SIGN; 2005.
18. Integraal Kankercentrum Nederland. Urotheelcarcinoom van de blaas. www.oncoline.nl/urotheelcarcinoom-van-de-blaas. Accessed February 2014.
19. A.M. Kamat, P.K. Hegarty, and J.R. Gee ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers Eur Urol 63 2013 4 15
20. Multi-disciplinary team (MDT) guidance for managing bladder cancer, ed 2. British Association of Urological Surgeons Web site. http://www.baus.org.uk/Resources/BAUS/Documents/PDF%20Documents/Sections/Oncology/MDT-GuidanceforProstateCancer.pdf.
21. C. Pfister, M. Roupret, and Y. Neuzillet Recommandations en onco-urologie 2013 du CCAFU: tumeur urothéliales Prog Urol 23 Suppl 2 2013 S105 S125
22. Associazione Italiana di Oncologia Medica (AIOM). Linee guida: carcinoma della vescica. www.aiom.it/area+pubblica/area+medica/prodotti+scientifici/linee+guida/ 1,333,1. Accessed February 2014.
23. A. Stenzl, D. Jocham, and P. Jichlinski Photodynamische Diagnostik im Harntrakt: Konsensusempfehlungen des Arbeitskreises Onkologie der Deutschen Gesellschaft für Urologie Urologe A 47 2008 982 987
24. J.A. Witjes, J.P. Redorta, and D. Jacqmin Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations Eur Urol 57 2010 607 614
25. C. Bunce, B.E. Ayres, and T.R. Griffiths The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer BJU Int 105 Suppl 2 2010 2 7
26. P.U. Malmstrom, M. Grabe, and E.S. Haug Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance Scand J Urol Nephrol 46 2012 108 116
27. Agrawal S, Mufti U, Rowland S, Hrouda D, Shamsuddin A. Diagnositic value of photodynamic (PDD) cystoscopy following BCG therapy using intravesical hexaminolavulinate [abstract MP-01.11]. Presented at: Société Internationale d'Urologie annual meeting; September 8-12, 2013; Vancouver, Canada.
28. R.O. Draga, M.C. Grimbergen, E.T. Kok, T.N. Jonges, C.F. van Swol, and J.L. Bosch Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guerin immunotherapy and mitomycin C intravesical therapy Eur Urol 57 2010 655 660
29. ®-guided fluorescence cystocsopy after BCG induction treatment. Poster 193 presented at: European Association of Urology Congress; April 16-20, 2010; Barcelona, Spain.
30. E.R. Ray, K. Chatterton, and M.S. Khan Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin BJU Int 105 2010 789 794
31. T. O'Brien, E. Ray, K. Chatterton, M.S. Khan, A. Chandra, and K. Thomas Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer BJU Int 112 2013 1096 1104
32. ®) en consultation pour le diagnostic des tumeurs de vessie Prog Urol 22 2012 172 177
33. G.G. Hermann, K. Mogensen, B.G. Toft, A. Glenthoj, and H.M. Pedersen Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies Scand J Urol Nephrol 46 2012 31 36
34. W. Loidl, J. Schmidbauer, M. Susani, and M. Marberger Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol 47 2005 323 326
35. J.A. Witjes, P.M. Moonen, and A.G. van der Heijden Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective phase II study Eur Urol 47 2005 319 322
36. A. Karl, S. Tritschler, and P. Stanislaus Positive urine cytology but negative white-light cystoscopy: an indication for fluorescence cystoscopy? BJU Int 103 2009 484 487
37. R.K. Loo, S.F. Lieberman, and J.M. Slezak Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria Mayo Clin Proc 88 2013 129 138
38. T.J. Edwards, A.J. Dickinson, S. Natale, J. Gosling, and J.S. McGrath A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic BJU Int 97 2006 301 305
39. H.B. Grossman, A. Stenzl, and Y. Fradet Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy J Urol 188 2012 58 62
40. M. Burger, D. Zaak, and C.G. Stief Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis Eur Urol 52 2007 142 147
41. M. Burger, S. Petschl, and B.G. Volkmer Kalkulation einer neuen Untersuchungs- und Behandlungsmethode (NUB): Analyse am Beispiel der PDD-gestützten TUR-B mit Hexaminolävulinsäure Urologe A 47 2008 1239 1244
42. S. Dindyal, T. Nitkunan, and C.J. Bunce The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer Photodiagnosis Photodyn Ther 5 2008 153 158
43. P.U. Malmstrom, H. Hedelin, Y.K. Thomas, G.J. Thompson, H. Durrant, and J. Furniss Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden Scand J Urol Nephrol 43 2009 192 198
44. W. Otto, M. Burger, and H.M. Fritsche Photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results? Clin Med Oncol 3 2009 53 58
45. Bennison C, Tempest M, Marteau F, et al. How investment in a hexaminolevulinate (HAL) technology would be beneficial to patients and healthcare systems in non-muscle invasive bladder cancer (NMIBC) in Italy [abstract S13-3]. Presented at: 10th Health Technology Assessment international annual meeting; June, 2013; Seoul, Korea.
46. F. Marteau, A. Kornowski, C. Bennison, M.J. Tempest, P. Mariappan, and J.A. Witjes Cost-effectiveness of the optical imaging agent hexaminolevulinate for patients undergoing initial transurethral resection of non-muscle invasive bladder cancer tumours [abstract 01] Eur Urol Suppl 12 2013 125
47. ®Observational Patients Evaluation) Prog Urol 23 2013 1123
48. H.M. Fritsche, W. Otto, and F. Eder Water-jet-aided transurethral dissection of urothelial carcinoma: a prospective clinical study J Endourol 25 2011 1599 1603
49. DRKS - Deutsches Register Klinischer Studien (German Clinical Trials Register). DRKS-ID: DRKS00004414. HYbrid knife in bladder cancer resection initially detected by Hexvix based blue-light enhancement (HybridBlue). http://www.germanctr.de. Accessed February 2014.